What's Trending

5 most popular innovation stories in Houston this week

From big accelerator news to a startup preventing flood damage, here are this week's top stories. Nick Bee/Pexels

Editor's note: Major accelerator news hit the headlines this week. MassChallenge Texas is wrapping up its inaugural Houston cohort — just as the new Ion Smart Cities Accelerator is launching. Meanwhile, on the heels of the second anniversary of Hurricane Harvey, a Houston startup has a solution to prevent flood damage.

Exclusive: New Houston accelerator reveals its inaugural cohort and announces strategic partner

The Ion Smart Cities Accelerator — named for its to-be home, The Ion — announced the 10 companies selected for the first cohort. Courtesy of Rice University

The Ion Smart Cities Accelerator launched earlier this year with a goal of engaging startups from around the world to solve some of Houston's most prevalent challenges. Backed by Intel and Microsoft and partnered with the city of Houston and Station Houston, the program has developed a curriculum and selected its first cohort.

Ten startups from around the world — half of which from right here in Houston — were selected to be a part of the program. And narrowing down to 10 was tough for the program's judges, says Christine Galib, director of the Ion Smart Cities Accelerator.

"Selecting the participants for our first cohort was difficult, due to this amazing pool of talent — that's always the problem you want to have," she tells InnovationMap.

Click here to continue reading.

3 Houston innovators to know this week

From oil and gas deals to finance-focused initiatives, this week's innovators are ones to watch. Courtesy photos

As Houstonians head back to work or school following a fun summer break, we know two things for sure.

The first is that traffic will get back to its headache inducing craziness and that Houston startup news will only get more frequent. This week's innovators to know include oil and gas entrepreneurs with big deals on the line plus a finance-savvy woman who wants to encourage others to take control of their personal finance.

Click here to continue reading.

MassChallenge Texas names top startups from its inaugural Houston cohort to move on to the final round

MassChallenge Texas named six companies, which will each pitch at a final competition on September 5. Photo via greenstreetdowntown.com

MassChallenge Texas revealed the cream of the crop from its first Houston cohort. The top six startups will now be judged in one final pitch competition on September 5.

"Each of the 25 startups in our first cohort have made incredible progress during this short program and are now better prepared to make impact in Houston, Texas, and beyond," says Jon Nordby, managing director of MassChallenge Texas in Houston, in a release. "It is our goal to strengthen the local ecosystem through a collaborative community that will attract innovators from around the world to Houston, and the Lone Star State."

Click here to continue reading.

A Texas organization has doled out millions to Houston cancer-fighting professionals

Texas doctors and researchers received millions for their transformational work in cancer prevention and treatment. Getty Images

Researchers at medical institutions across the state have something to celebrate. The Cancer Prevention and Research Institute of Texas has made 71 grants this week to cancer-fighting organizations that total a near $136 million.

"CPRIT's priorities of pediatric cancer research and cancers of significance to Texans highlight this large slate of awards," says Wayne Roberts, CPRIT CEO, in a release. "Investments are made across the cancer research and prevention continuum in Texas unlike any other state in the country."

New to the awards this time around is the Collaborative Action Program for Liver Cancer, which has been claimed by Baylor College of Medicine's Hashem B. El-Serag.

Click here to continue reading.

Houston startup is providing self-deploying flood damage prevention technology

A Houston entrepreneur has brought in a technology to prevent major flood damage. Photo courtesy of HAR

Tasha Nielsen was on a trip to Denmark when she came across a Danish company making strides in flood prevention techniques.

"We were visiting family one day when we turn on the news and see FloodFrame's brand launch," Nielsen says. "The inventors live in Denmark, and they've done installations in Denmark, Germany and England, and they've been very successful."

That company partnered with the Danish Technological Institute and the Danish Hydraulic Institute and worked for years perfecting their flood prevention system. After Nielsen asked whether she could contract FloodFrame to install their system at her home back in Houston, she learned the founders weren't interested in coming over themselves to expand their business to the United States.

Click here to continue reading.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News